Establishment Labs
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company...
Latest News
19 days ago · seekingalpha.com
Establishment Labs Holdings Inc. (ESTA) Q3 2026 Earnings Call TranscriptEstablishment Labs Holdings Inc. (ESTA) Q3 2026 Earnings Call Transcript
19 days ago · zacks.com
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Beats Revenue EstimatesEstablishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.38 per share a year ago.
19 days ago · marketbeat.com
What Establishment Labs (ESTA) Said on Its Q3 Earnings CallEstablishment Labs NASDAQ: ESTA reported third-quarter revenue growth of 33.9% year over year to $72 million, driven by U.S. market-share gains and expansion across international markets, while the company generated positive free cash flow for the first time in its history.
26 days ago · zacks.com
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Should You Buy?Establishment Labs (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
29 days ago · businesswire.com
Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2026, before the market opens on Thursday, October 29, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results.To participate in the conference call, Dial: (+1) 877-407-8037 (US.
2 months ago · businesswire.com
Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic ImplantsNEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform. Establishment Labs also announced the product line extensions of both Mia® and Preservé™ with new sizes and supporting tools. The announcements.
2 months ago · seekingalpha.com
Establishment Labs: Procedure Economics Strengthens The Bull CaseEstablishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth. Preservé delivers over 2x revenue per procedure versus traditional augmentation, but long-term success hinges on repeat utilization and durable economics.
3 months ago · seekingalpha.com
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call TranscriptEstablishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript
3 months ago · marketbeat.com
Establishment Labs Q2 Earnings Call HighlightsEstablishment Labs NASDAQ: ESTA reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage.
3 months ago · zacks.com
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue EstimatesEstablishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.57 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ESTA